tci Medicare Compliance & Reimbursement - 2004 Issue 20
Oncologists: Oncologists To CMS: Give Us The Bad News First
Subscribe or sign in to view the full article.
Article Overview
This article covers Medicare payment policy issues affecting oncology practices, with emphasis on chemotherapy drug reimbursement, drug administration fees, and the transition to ASP-based payment. It explains why oncologists, professional societies, and legislators are urging CMS to release pricing information sooner, and it provides policy context around expected reimbursement changes and their potential impact on cancer care. The piece is most relevant to oncology practices, medical coders, billing staff, and policy watchers following Medicare payment updates.
Why This Topic Matters
Changes in Medicare reimbursement for oncology drugs and administration services can affect practice revenue, access to care, and planning for upcoming payment-year updates. Readers following oncology billing and federal payment policy will want to understand the timing and uncertainty surrounding CMS rate information.
What You Will Learn
- How Medicare policy changes are affecting oncology drug and service payments
- Why CMS pricing data is important to oncology reimbursement planning
- How professional societies and legislators are responding to payment uncertainty
- What broader congressional and administrative timing issues may influence future payment changes
Who Should Read This
- Oncology practices
- Medical coders
- Billing and reimbursement staff
- Practice administrators
- Healthcare policy analysts
Subscribe or sign in to view the full article.
Thank you for choosing Find-A-Code, please Sign In to remove ads.
Quick, Current, Complete - www.findacode.com